Does United Healthcare Cover Weight Loss Injections?

UnitedHealthcare does cover weight loss injections such as Wegovy, Zepbound, and Saxenda, but only on plans that have been set up to include them and only when the patient meets specific clinical criteria. For most employer-sponsored plans, the employer decides whether weight loss drugs are a covered benefit at all. For individual, Medicare, and Medicaid plans, the answer is tighter still.

Whether Your Plan Covers Them At All

The first question is not clinical. It is whether your specific plan includes weight loss medications as a benefit. UHC treats this as an optional add-on for employer-sponsored coverage, and in its own materials for brokers has stated that “many employer groups still don’t cover drugs for obesity or weight loss at all.”¹

When an employer does opt in, UHC administers coverage through its clinical pharmacy program. Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide) are all available as covered weight loss injections on those plans, each subject to prior authorization.² When an employer has not elected the benefit, weight loss drugs are treated as a plan exclusion.³

State law changes the picture in a few places. UHC’s weight loss medication program is built to meet mandates in California, New Mexico, New York, and North Dakota, where certain plans must cover these drugs as part of essential health benefits.² Outside those states, individual and ACA marketplace plans tend to be more limited, with formularies often restricted to older oral weight management drugs like Contrave and Qsymia rather than the newer GLP-1 injections.

Some employer plans add another layer: more than one-third of employers who cover weight loss drugs now require participation in a weight management coaching program as a condition of GLP-1 coverage.¹ If your plan does, you’ll need to enroll or engage before medication coverage activates.

Clinical Criteria You Have to Meet

Even on a plan that covers these drugs, approval is not automatic. UHC requires prior authorization and applies specific medical criteria that must be documented before a prescription is paid.

The core requirements are similar across all three injections. The medication must be prescribed alongside lifestyle modifications such as diet, exercise, or behavioral counseling, consistent with FDA labeling. On top of that, you must meet one of two BMI thresholds:²

A BMI of 30 or higher (or above the 95th percentile for pediatric patients), or
A BMI of 27 or higher with at least one weight-related health condition such as type 2 diabetes, high blood pressure, sleep apnea, or high cholesterol.

Age cutoffs vary by drug. Wegovy and Saxenda are approved for patients 12 and older. Zepbound requires the patient to be over 16.²

North Dakota fully insured plans that cover these medications under the state’s essential health benefit rules apply a stricter threshold, requiring a BMI of 40 or higher for initial authorization, unless the request is for Wegovy to treat metabolic dysfunction-associated steatohepatitis (MASH).²

Keeping Coverage After the First Authorization

Initial authorizations are short. Wegovy is approved for 5 months, Zepbound for 6 months, and Saxenda for 4 months.

After that, your provider has to submit a reauthorization request, and continued coverage is granted in 12-month increments only if you show measurable progress. For Wegovy and Zepbound, UHC requires documentation of at least 5% weight loss from baseline, plus continued lifestyle modification. Saxenda’s threshold is 4% of baseline body weight.² Patients who don’t hit the benchmark during the initial period will typically lose coverage through the standard weight loss pathway.

If Weight Loss Is Excluded, There May Still Be a Path

Plans that exclude weight loss drugs sometimes still cover Wegovy and Zepbound for other FDA-approved uses. UHC maintains separate “nonformulary” criteria for these cases.

Wegovy may be approved on an excluded plan in two situations: cardiovascular risk reduction in patients 45 and older with established heart disease (such as a prior heart attack, stroke, or peripheral artery disease) and a BMI of 27 or higher, and treatment of MASH with moderate to advanced liver fibrosis. These criteria are more restrictive than the weight loss pathway and require documentation of specific concurrent therapies and specialist involvement.³

Zepbound’s nonformulary pathway covers moderate to severe obstructive sleep apnea. The patient must be 18 or older, have a BMI of 30 or higher, have sleep apnea confirmed by a sleep study, and have either tried positive airway pressure therapy without adequate relief or been determined to be a poor candidate for it. A prescription from or in consultation with a sleep specialist is required.⁴

Medicare and Medicaid

Medicare Part D has historically not covered medications prescribed solely for weight loss. That is shifting in a limited way through a federal program called the Medicare GLP-1 Bridge, which starts July 1, 2026, and gives Medicare beneficiaries access to Wegovy, Zepbound, and a newer drug called Foundayo for weight loss. The program runs through at least the end of 2026 and is administered centrally by CMS through Humana as the claims processor, not through individual Part D plans like UHC’s Medicare Advantage products.⁵

Under the Bridge, eligible beneficiaries pay a flat $50 copay per prescription, which does not count toward the Part D deductible or out-of-pocket limits. Eligibility is based on BMI: 35 or higher qualifies regardless of other conditions, while lower thresholds (30 or 27) apply for patients with diagnoses such as heart failure, chronic kidney disease, or pre-diabetes.⁵ Because the program sits outside Part D, UHC Medicare Advantage members access it by having their provider submit prior authorization directly to the central processor rather than to UHC. A longer-term program called the BALANCE Model was originally expected in January 2027, but CMS announced in spring 2026 that its Part D component has been delayed indefinitely.⁶

Medicaid coverage through UHC Community Plan varies by state. In New York, anti-obesity agents are explicitly excluded from the Community Plan’s preferred drug list.³ More broadly, as of January 2026, only 13 state Medicaid programs cover GLP-1 drugs for obesity, and that number has fallen in recent months as states including California, New Hampshire, and Pennsylvania dropped coverage. Federal law lets state Medicaid programs exclude weight loss drugs even though they must cover the same medications when prescribed for diabetes or cardiovascular disease.⁷

What You’ll Pay

UHC does not publish a single cost schedule for weight loss injections. Copays and coinsurance depend on the employer and plan design, which is why checking your own benefits is the only reliable way to know your cost.⁸

Patterns do show up in available formularies. On at least one OptumRx-managed formulary for 2026, Wegovy, Saxenda, and Zepbound auto-injectors sit at Tier 2 (preferred brand) with prior authorization and quantity limits.⁹ On other plans these drugs land on higher specialty tiers with correspondingly higher cost-sharing.

Manufacturer savings programs can bring the price down for commercially insured patients. Eli Lilly’s Zepbound Savings Card lets eligible patients with commercial coverage pay as little as $25 per monthly fill, with annual savings capped at $1,300. A separate version of the card is available for patients whose insurance does not cover Zepbound, bringing the price to as low as $499 per month.¹⁰ These programs are not available to Medicare, Medicaid, or TRICARE beneficiaries, and they are set to expire at the end of 2026.

If You’re Denied

A denial is not the end of the road. UHC members can appeal, and the process depends on the plan type.

For Medicare Part D denials, start by requesting a coverage determination from OptumRx, which can be done online, by phone (1-800-711-4555), or by fax. If that comes back unfavorable, you have 65 days to file a formal appeal, called a redetermination, by mail, fax, or email. Standard appeals are decided within 7 calendar days. Expedited appeals, available when a delay could harm your health, must be resolved within 72 hours. If UHC misses the deadline, the case automatically advances to an independent review.¹¹

For commercial plan denials, your provider can request a peer-to-peer review with a UHC medical director. For inpatient cases that generally has to happen within 24 hours of the denial, and for outpatient requests within 21 calendar days. UHC recommends digital submission for all appeals and reconsiderations.¹²

The strongest appeals come with detailed clinical documentation of medical necessity: your weight history, evidence of failed lifestyle interventions, documentation of weight-related conditions, and clinical data supporting the specific medication. If the denial is based on a plan exclusion rather than a clinical judgment, the appeal needs to address the exclusion itself. The drug manufacturers also publish template letters and resources to help with appeals.¹³

How to Check Your Own Coverage

Because the answer varies so much by plan, employer, and state, the only way to know for certain is to check your specific benefits. Sign in at member.uhc.com or through the UHC mobile app to view your pharmacy benefits and prescription drug list. Or call the member services number on the back of your card and ask a representative to confirm whether weight loss injections are covered on your plan, what prior authorization requires, and what your cost-sharing will be.⁸

1
UnitedHealthcare. Sustainable Weight Management
2
UHC Provider. Prior Authorization Notification – Weight Loss
3
UHC Provider. Non-Formulary Wegovy Criteria
4
UHC Provider. Non-Formulary Zepbound Criteria
5
CMS. Medicare GLP-1 Bridge
6
Medicare Rights Center. GLP-1 Weight Loss Drug Demonstration Begins July 2026
7
KFF. Medicaid Coverage of and Spending on GLP-1s
8
UnitedHealthcare. Prescription Drug Lists
9
OptumRx. 2026 Premium Formulary Booklet
10
Eli Lilly. Zepbound Savings
11
UnitedHealthcare. Prescription Drug Appeals
12
UHC Provider. Appeals
13
Medical News Today. How to Appeal a Wegovy Denial